Patents Represented by Attorney Polsinelli Shughart PC
  • Patent number: 7853437
    Abstract: A system and method for detecting and identifying electronic devices based on their unintended electromagnetic emissions (“UEE”) signals is presented. During device classification, UEE signals are measured from a plurality of test devices and characteristic data is obtained from the UEE signal emitted from each test device. Using the characteristic data, a threshold value and ideal pulse template can be determined for each test device and stored in a memory. An ideal stimulation signal is also determined for each test device and stored in the memory. During device detection, the ideal stimulation signal is applied to the environment in which a target device is suspected of being located. Stimulated UEE signals are measured from the target device and processed. The processed measurement data is compared to stored power threshold values and ideal pulse templates to determine if the target device is present.
    Type: Grant
    Filed: December 1, 2008
    Date of Patent: December 14, 2010
    Assignee: The Curators of the University of Missouri
    Inventors: Sarah A. Seguin, Daryl G. Beetner, Todd H. Hubing
  • Patent number: 7850740
    Abstract: Provided is a prosthesis system for indirectly coupling a prosthesis to the skeletal structure of a person. The system includes a plurality of individual magnets and magnet sets attached to a prosthetic socket of a prosthetic device. The magnets may be permanent magnets or electromagnets. A second plurality of magnets is embedded within a residual limb of a person, mounted to or within a sub-dermal strut. In operation, the magnetic fields generated by the magnets of the prosthetic socket, which may be dynamic magnetic fields, interact with the magnetic fields generated by the magnets anchored beneath the skin of the person, to hold the prosthetic device in position during use. A power supply provides current to any electromagnets, and a controller alters any required magnetic fields based on input received from both load and position sensors in the sub-dermal strut.
    Type: Grant
    Filed: April 3, 2008
    Date of Patent: December 14, 2010
    Assignee: Teledyne Scientific & Imaging, LLC
    Inventors: Brian N. Cox, Mohsen Khoshnevisan, Douglas G. Smith
  • Patent number: 7851436
    Abstract: The present invention provides combinations and methods for inducing cell death, inhibiting angiogenesis, and inhibiting cell migration. In particular, the present invention provides methods for inducing cell death in a cell expressing an ?v?3 and/or an ?v?5 integrin.
    Type: Grant
    Filed: April 7, 2008
    Date of Patent: December 14, 2010
    Assignee: Washington University
    Inventors: Linda Sandell, Zhepeng Wang
  • Patent number: 7850483
    Abstract: A one-piece power meter socket to circuit breaker connection structure includes an elongated trunk section connecting a lower spade section with a forwardly offset connection plate at an upper end. The connection plate is joined to the trunk section by an angled extension section. The connection plate has an aperture to receive a fastener to connect it and a meter jaw to a meter jaw base. The spade section includes a pair of laterally spaced, forwardly projection breaker receiving spades for reception in a receptacle of a circuit beaker. The connection structures are used in pairs with an insulating circuit breaker base to connect load-side meter jaws of a power meter socket to spade receptacles of a plug-in type of circuit breaker. The one-piece connection structure is formed of a sheet of metal having a thickness equal to the thickness specified for the spades engaged by the circuit breaker.
    Type: Grant
    Filed: August 18, 2008
    Date of Patent: December 14, 2010
    Assignee: Milbank Manufacturing Co.
    Inventors: John V. Siglock, Shawn J. Glasgow
  • Patent number: 7851463
    Abstract: The invention relates to compounds of the formula (I). The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: December 14, 2010
    Assignee: Abbott GmbH & Co. KG
    Inventors: Karla Drescher, Andreas Haupt, Liliane Unger, Sean C. Turner, Wilfried Braje, Roland Grandel, Christophe Henry, Gisela Backfisch, Armin Beyerbach, Wilfried Lubisch
  • Patent number: 7845870
    Abstract: A multi-positional, multi-level user interface system including a keyboard hinged over a base surface for a pointing device such as a mouse. The keyboard and base rotate relative to each other about a hinge axis to reveal the surface, providing a portable keyboard and pointing surface. A kickstand can support the keyboard above the base while in an open position. The keyboard and pointing device can be used with two hands with the system resting in a user's lap. The keyboard can also swivel about an axis other than the hinge axis. The keyboard can swivel 180 degrees for left-handed use, and can be positioned at other detent angles. A mouse can also be stowed on the base with a magnetic, friction, or other coupling. The interface system can further act as a communication hub for other peripheral devices, such as a joystick, to communicate with a computing device.
    Type: Grant
    Filed: May 4, 2005
    Date of Patent: December 7, 2010
    Assignee: Infinum Labs, Inc.
    Inventors: Eric J. Hull, Jeffrey D. Allison, Tyrol R. Graham, Ryan T. Lane
  • Patent number: 7842800
    Abstract: The present invention relates to a first group of novel bacterial and human associated oligonucleotides, here identified as Genomic Address Messenger or GAM oligonucleotide, and a second group of novel operon-like bacterial and human polynucleotides, here identified as Genomic Record or GR polynucleotide. GAM oligonucleotides selectively inhibit translation of known ‘target’ genes, many of which are known to be involved in various bacterial diseases. Nucleic acid molecules are provided respectively encoding 6444 GAM precursors oligonucleotides, and 726 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.
    Type: Grant
    Filed: April 2, 2004
    Date of Patent: November 30, 2010
    Assignee: Rosetta Genomics Ltd.
    Inventor: Itzhak Bentwich
  • Patent number: 7842767
    Abstract: The present invention relates to a cross-linked polyether which is obtained by polymerization of at least one monomer selected from the group consisting of (a) (?-X-methyl) vinyl-EWG, (?-X-methyl) vinyl-ERG, or (?-X-methyl) vinyl-aryl, where X is oxygen, sulfur, PEG, PPG or poly (THF); (b) a monomer which is polymerizable with a PEG, PPG or poly (THF) cross-linker having at least one (?-X-methyl) vinyl-EWG, (?-X-methyl) vinyl-ERG or (?-X-methyl) vinyl-aryl, where X is oxygen, sulfur, PEG, PPG, or poly (THF); (c) a PEG, PPG, or poly (THF) cross-linker having at least an acrylamide or a methacrylamide end group; and (d) mixtures thereof. Various monomers, resins and methods for preparing such cross-linked polyethers are also disclosed.
    Type: Grant
    Filed: August 4, 2004
    Date of Patent: November 30, 2010
    Assignee: Matrix Innovation Inc.
    Inventor: Simon Côté
  • Patent number: 7839212
    Abstract: A two stage fully differential amplifier has been designed which works, in tandem with a TX-FIR, as a linear equalizer at low frequencies, not covered by the TX-FIR, and also acts as a linear amplifier at higher frequencies which are equalized by the TX-FIR. The amplifier as a frequency response which does not attenuate signals frequencies less than one twentieth of baud rate, creates gain peaking ion the region between one twentieth and one tenth of baud rate and maintains flat peak gain up to half of baud rate. Different aspects of the frequency response curve (such as dc gain, max gain and zero frequency) are completely programmable. Also, the differential amplifier has been designed from low power and process, voltage and temperature insensitive frequency response.
    Type: Grant
    Filed: December 4, 2008
    Date of Patent: November 23, 2010
    Assignee: Oracle America, Inc.
    Inventors: Dawei Huang, Arif Amin, Waseem Ahmad, Rajesh Kumar, Venkatesh Arunachalam
  • Patent number: 7834048
    Abstract: The present invention relates to a compound of the formula (I) wherein R1 is H, C1-C6-alkyl which may be substituted by C3-C6-cycloalkyl, fluorinated C1-C6-alkyl, C3-C6-cycloalkyl, fluorinated C3-C6-cycloalkyl, C3-C6-alkenyl, fluorinated C3-C6-alkenyl, formyl, acetyl or propionyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one or more substituents selected from halogen, methyl, methoxy and CF3; E is NR5 or CH2, wherein R5 is H or C1-C3-alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8 is H, C1-C4-alk
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: November 16, 2010
    Assignee: Abbott GmbH & Co. KG
    Inventors: Karla Drescher, Andreas Haupt, Liliane Unger, Sean C. Turner, Wilfried Braje, Roland Grandel
  • Patent number: 7833713
    Abstract: A novel method of suppressing non-specific cross-hybridization between repetitive elements present in nucleic acid probes and corresponding repetitive elements in the target nucleic acid by using DNA synthesized to contain a plurality of repetitive elements while avoiding low and single copy sequences.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: November 16, 2010
    Assignee: The Children's Mercy Hospital
    Inventors: Peter K. Rogan, Joan Knoll, Heather Newkirk
  • Patent number: 7835058
    Abstract: A switchable apochromatic polarization rotator is provided. A first fixed waveplate has a first principal axis fixed in a first orientation. A second fixed waveplate has a second principal axis fixed in a second orientation. First and second switchable waveplates have principal axes oriented such that broad spectral range electromagnetic radiation transmitted through all of the waveplates has a first rotated polarization, wherein, in response to one or more control signals applied to the switchable waveplates, the principal axes of the switchable waveplates rotate such that the electromagnetic radiation transmitted through all of the waveplates has a second rotated polarization. The switchable waveplates utilize ferroelectric liquid crystal material, nematic liquid crystal material, or be mechanically rotated to adjust for orientation of their principal axes. Utilizing waveplates as described may be used to tune for a desired spectral range and/or compensate for temperature dependencies.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: November 16, 2010
    Assignee: Teledyne Scientific & Imaging, LLC
    Inventors: Bing Wen, Milind P. Mahajan, Bruce K Winker
  • Patent number: 7834012
    Abstract: The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II, as well as hyperglycemia, metabolic syndrome, hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory diseases, and other diseases.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: November 16, 2010
    Assignee: Abbott Laboratories
    Inventors: Zhonghua Pei, Thomas von Geldern, David J. Madar, Xiaofeng Li, Fatima Basha, Hong Yong, Kenton L. Longenecker, Bradley J. Backes, Andrew S. Judd, Mathew M. Mulhern, Kent D. Stewart
  • Patent number: 7831791
    Abstract: A system and method for address space layout randomization (“ASLR”) for a Windows operating system is disclosed. The address space layout includes one or more memory regions that are identified and then a particular implementation of the system randomizes the identified memory region in order to prevent any software vulnerabilities.
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: November 9, 2010
    Assignee: Wehnus, LLC
    Inventors: Matthew Miller, Ken Johnson
  • Patent number: 7829661
    Abstract: The present invention provides a family of peptides based upon the M2GlyR sequence. These peptides are derivatives of the M2GlyR sequence and can be modified at their ends to include a plurality of polar amino acid residues to enhance their solubility. Particularly preferred derivatives include portions of the M2GlyR sequence which are palindromic to another portion of the peptide or to the M2GlyR sequence itself. Preferably these portions are at least 7 amino acid residues in length. Peptides embraced by the present invention are characterized by having greater effects on the transepithelial electrical resistance of cells at lower concentrations. Peptides of the present invention have been shown to increase Isc in MDCK epithelial cell monolayers with half maximal effects observed at or below 30 ?M, a nearly 10-fold improvement over any peptide previously characterized in the M2GlyR family.
    Type: Grant
    Filed: June 14, 2004
    Date of Patent: November 9, 2010
    Assignee: Kansas State University Research Foundation
    Inventors: John M. Tomich, Iwamoto Takeo, James R. Broughman, Bruce D. Schultz
  • Patent number: 7828127
    Abstract: A rotary damper allows for fluid bypass through the interior of the hydraulic chamber, as opposed to dampers where fluid bypass occurs only along the walls of the hydraulic chamber. Additionally, the damper accommodates bi-directional damping, by providing a universal piece and switching the position of a component in the piece.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: November 9, 2010
    Assignee: Austin Hardware & Supply, Inc.
    Inventor: Mark Jeffries
  • Patent number: 7831961
    Abstract: By encoding an exception triggering value in storage referenced by an instruction in an otherwise unused slot (e.g., the delay slot of a delayed control transfer instruction or an unused instruction position in a VLIW-based architecture) coinciding with a safe point, an efficient coordination mechanism can be provided for multi-threaded code. Because the mechanism(s) impose negligible overhead when not employed and can be engaged in response to an event (e.g., a start garbage collection event), safe points can be defined at call, return and/or backward branch points throughout mutator code to reduce the latency between the event and suspension of all threads. Though particularly advantageous for thread suspension to perform garbage collection at safe points, the techniques described herein are more generally applicable to program suspension at coordination points coinciding with calls, returns, branches or calls, returns and branches therein.
    Type: Grant
    Filed: March 13, 2006
    Date of Patent: November 9, 2010
    Assignee: Oracle America, Inc.
    Inventors: William Bush, Mario I. Wolczko, Marc Tremblay
  • Patent number: 7825229
    Abstract: Described are polynucleotides associated with lung cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that can be used for diagnosis, prognosis, and treatment of lung cancer. Also described are methods that can be used to identify modulators of the disease-associated polynucleotides. Also described are methods and compositions for linear amplification and labeling of a targeted nucleic acid. The amplified targeted molecules may be used in hybridization techniques like Luminex and Microarray analysis.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: November 2, 2010
    Assignee: Rosetta Genomics Ltd.
    Inventors: Bentwich Itzhak, Amir Avniel, Yael Karov, Ranit Aharonov
  • Patent number: 7825101
    Abstract: In various aspects and embodiments the invention provides methods and reagents for controlling gene expression, and for treating disorders and diseases. Embodiments provide methods and reagents specifically for the regulation of MLCK expression and for the use thereof in treating disorders and diseases. Various embodiments provide methods and reagents for specifically down regulating the expression of MLCK-L more efficiently than that of MLCK-S, and for the use thereof in treating disorders and diseases. Embodiments provide siNA for the same, particularly siRNAs. Various of the embodiments are useful for the treatment of inflammatory disorders and diseases, including, for one example in this regard, Asthma.
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: November 2, 2010
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Dolly Mehta, Shahid S. Siddiqui, Asrar Malik
  • Patent number: D626434
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: November 2, 2010
    Assignee: Hillyard Enterprises, Inc.
    Inventors: Rocky Massin, Joe Kauth, Matt Johnston, Craig Snider